Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be Monitored 

Laurence Klotz, MD, outlines recent progress in active surveillance (AS), highlighting molecular genetics of GG1 vs. higher grade cancers, patient selection, germline testing, imaging, biomarkers, predictive nomograms, modeling, long-term outcomes, follow-up strategies, the tumor microenvironment, and dietary modifications. Dr. Klotz summarizes current AS follow-up strategy and explains that an emerging strategy is dynamic risk profiling with accurate biomarkers that will replace most serial biopsies.
More from Dr. Klotz on Grand Rounds in Urology: grandroundsinu...